Celldex Therapeutics, Inc. (CLDX) Given Consensus Recommendation of “Hold” by Brokerages

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has earned a consensus rating of “Hold” from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $7.50.

CLDX has been the subject of a number of research reports. BidaskClub cut shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. Cantor Fitzgerald restated a “buy” rating and set a $9.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. WBB Securities restated a “buy” rating and set a $10.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, December 6th. Finally, HC Wainwright restated a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th.

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Celldex Therapeutics by 7.8% in the second quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock valued at $24,143,000 after buying an additional 708,095 shares during the last quarter. Meditor Group Ltd increased its position in Celldex Therapeutics by 8.8% during the third quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock worth $18,054,000 after purchasing an additional 512,700 shares during the last quarter. Northern Trust Corp increased its position in Celldex Therapeutics by 12.2% during the second quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock worth $4,992,000 after purchasing an additional 219,661 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Celldex Therapeutics by 3.6% during the third quarter. Dimensional Fund Advisors LP now owns 861,790 shares of the biopharmaceutical company’s stock worth $2,465,000 after purchasing an additional 29,604 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Celldex Therapeutics by 3.6% during the third quarter. Bank of New York Mellon Corp now owns 622,430 shares of the biopharmaceutical company’s stock worth $1,780,000 after purchasing an additional 21,905 shares during the last quarter. 52.46% of the stock is owned by institutional investors and hedge funds.

Celldex Therapeutics (CLDX) traded down $0.06 during mid-day trading on Tuesday, reaching $2.80. 1,127,600 shares of the company were exchanged, compared to its average volume of 1,225,978. The stock has a market capitalization of $364.44, a P/E ratio of -2.77 and a beta of 2.73. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $3.94.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.07. The firm had revenue of $3.90 million for the quarter, compared to the consensus estimate of $1.30 million. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. The firm’s revenue was up 77.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.29) earnings per share. analysts predict that Celldex Therapeutics will post -0.93 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Celldex Therapeutics, Inc. (CLDX) Given Consensus Recommendation of “Hold” by Brokerages” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/16/celldex-therapeutics-inc-cldx-given-consensus-recommendation-of-hold-by-brokerages.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply